Back to Search
Start Over
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
- Source :
- European heart journal. 40(19)
- Publication Year :
- 2018
-
Abstract
- Aims To investigate the relationship between body mass index (BMI) and outcomes in patients with atrial fibrillation (AF). Methods and results In the ENGAGE AF-TIMI 48 trial, patients with AF were randomized to warfarin (international normalized ratio 2.0–3.0) or edoxaban. The cohort (N = 21 028) included patients across BMI categories (kg/m2): underweight (18.5 kg/m2, while time in therapeutic range for warfarin improved significantly as BMI increased (P Conclusion An increased BMI was independently associated with a lower risk of stroke/SEE, better survival, but increased risk of bleeding. The efficacy and safety profiles of edoxaban were similar across BMI categories ranging from 18.5 to >40.
- Subjects :
- Male
medicine.medical_specialty
Pyridines
Embolism
Hemorrhage
Comorbidity
030204 cardiovascular system & hematology
Lower risk
Body Mass Index
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Edoxaban
Internal medicine
Atrial Fibrillation
medicine
Humans
Obesity
Stroke
Aged
Proportional Hazards Models
Aged, 80 and over
business.industry
Warfarin
nutritional and metabolic diseases
Anticoagulants
Atrial fibrillation
030229 sport sciences
Middle Aged
Overweight
medicine.disease
Thiazoles
Treatment Outcome
chemistry
Female
Underweight
medicine.symptom
Cardiology and Cardiovascular Medicine
business
Body mass index
TIMI
medicine.drug
Factor Xa Inhibitors
Subjects
Details
- ISSN :
- 15229645
- Volume :
- 40
- Issue :
- 19
- Database :
- OpenAIRE
- Journal :
- European heart journal
- Accession number :
- edsair.doi.dedup.....835f6ac91079fd375b3cbd0613b7278c